期刊
CLINICA CHIMICA ACTA
卷 444, 期 -, 页码 81-85出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2015.01.039
关键词
EGFR; T790M; Mutation; Resistance; Non small-cell lung cancer
Lung cancer patients carrying sensitive epidermal growth factor receptor (EGFR) mutations show dramatic responses to tyrosine kinase inhibitors (TKIs). However, the majority of patients whose disease responds to drugs eventually develop resistance to these EGFR-TKIs. The T790M gatekeeper mutation in the EGFR tyrosine kinase domain accounts for half of resistance to these drugs. In some patients, this mutation is also detected as a primary event before drug exposure, at a frequency that is highly dependent on the technique used. This review will focus on the methods that have been used to detect the T790M mutation, and its potential clinical applications both in TKI naive patients and in patients with an acquired resistance. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据